Press release
Oncolytic Virus Cancer Therapy Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024
Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report
* DelveInsight's Oncolytic Virus Cancer Therapy pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Oncolytic Virus Cancer Therapy treatment.
* The leading Oncolytic Virus Cancer Therapy Companies working in the market include Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Turnstone Biologics, and others.
* Promising Oncolytic Virus Cancer Therapy in the various stages of development include ONCOS-102, gemcitabine, VRT106, CG0070, Keytruda, pembrolizumab, TILT-123, and others.
* April 2024:- Guangzhou Virotech Pharmaceutical Co., Ltd.- A Phase I Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics, Biological Effects and Initial Efficacy of Recombinant Oncolytic Virus M1 for Injection (VRT106) in the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors.
* April 2024:- Mridula George, MD- This is a phase 2 study to evaluate the safety and efficacy of the combination of INCMGA00012 and pelareorep and to see how well they work in treating patients with triple negative breast cancer that has spread to other parts of the body (metastatic).
Request a sample and discover the recent advances in Oncolytic Virus Cancer Therapy treatment drugs @ Oncolytic Virus Cancer Therapy Pipeline Outlook Report [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Oncolytic Virus Cancer Therapy Overview
Oncolytic virotherapy is a treatment of using a virus that can replicate itself to kill cancer cells. There are many species of viruses, but not all of them can be designed to be an oncolytic virus (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity of being transformed to express tumor-killing factors through genetic engineering methods. Tumor selectivity could be concerned with the level of receptor-mediated cell entry, intracellular antiviral responses, or restriction factors that determine the susceptibility of the infected cell that leads to viral gene expression and replication.
Oncolytic Virus Cancer Therapy Emerging Drugs Profile
* Olvi-Vec: Genelux Corporation
* CAN-2409: Candel Therapeutics
* CG0070: CG Oncology
* Pelareorep: Oncolytics Biotech
* ParvOryx: Oryx GmbH
* SND005: Jiangsu Sinorda Biomedicine
* VCN-01: VCN Biosciences
Find out more about Oncolytic Virus Cancer Therapy treatment drugs @ Drugs for Oncolytic Virus Cancer Therapy Treatment [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Oncolytic Virus Cancer Therapy Therapeutics Assessment
There are approx. 120+ key Oncolytic Virus Cancer Therapy companies which are developing the therapies for Oncolytic Virus Cancer Therapy. The Oncolytic Virus Cancer Therapy companies which have their Oncolytic Virus Cancer Therapy drug candidates in the most advanced stage, i.e. phase III include, Genelux Corporation.
DelveInsight's Oncolytic Virus Cancer Therapy report covers around 125+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Learn more about the emerging Oncolytic Virus Cancer Therapy pipeline therapies @ Oncolytic Virus Cancer Therapy Clinical Trials [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intranasal
* Intravenous
* Oral
* Oral/Intravenous
* Parenteral
* Subcutaneous
* Subcutaneous/Intramuscular
Oncolytic Virus Cancer Therapy Products have been categorized under various Molecule types such as
* Oncolytic Viruse
Oncolytic Virus Cancer Therapy Companies
Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Turnstone Biologics, and others.
Dive deep into rich insights for new drugs for Oncolytic Virus Cancer Therapy Treatment, visit @ Oncolytic Virus Cancer Therapy Drugs [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Oncolytic Virus Cancer Therapy Pipeline Report
* Coverage- Global
* Oncolytic Virus Cancer Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Oncolytic Virus Cancer Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Oncolytic Virus Cancer Therapy Companies- Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Turnstone Biologics, and others.
* Oncolytic Virus Cancer Therapy Therapies- ONCOS-102, gemcitabine, VRT106, CG0070, Keytruda, pembrolizumab, TILT-123, and others
For further information on the Oncolytic Virus Cancer Therapy Pipeline Therapeutics, reach out @ Oncolytic Virus Cancer Therapy Treatment Drugs [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Oncolytic Virus Cancer Therapy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Oncolytic Virus Cancer Therapy- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Olvi-Vec: Genelux Corporation
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SND005: Jiangsu Sinorda Biomedicine
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* AloCelyvir: Orgenesis
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* VCN-01: VCN Biosciences
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* SynOV 1.3: Beijing Syngentech
* Drug profiles in the detailed report.....
* Inactive Products
* Oncolytic Virus Cancer Therapy Key Companies
* Oncolytic Virus Cancer Therapy Key Products
* Oncolytic Virus Cancer Therapy- Unmet Needs
* Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
* Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
* Oncolytic Virus Cancer Therapy Analyst Views
* Oncolytic Virus Cancer Therapy Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=oncolytic-virus-cancer-therapy-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oncolytic Virus Cancer Therapy Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 here
News-ID: 3491629 • Views: …
More Releases from ABNewswire
98% Consistency, 0 Staff: Anno Robot Redefines Airport Coffee in 60 Countries
As millions of travellers rush through terminals worldwide, one constant complaint has finally been solved: bad airport coffee served slowly by exhausted staff. Shenzhen-based Anno Robot [https://www.coffeerobotsanno.com/] has quietly eliminated both problems with fully robotic kiosks that deliver 98% brew-to-brew consistency and require zero human baristas. By November 2025, these AI-powered stations are operating in airports and high-traffic hubs across more than 60 countries, marking a turning point for the…
FAXVIN Unveils Enhanced CarRank, a 0-100 Single-Score Summary That Makes Used-Ca …
Updated methodology brings additional partner data and refined signal weighting so shoppers and dealers can rank and compare vehicles in seconds.
WALNUT, Calif. - Nov. 19, 2025 - FAXVIN today announced a significant update to CarRank, its 0-100 vehicle-history metric designed to help shoppers and dealers compare used cars at a glance. The latest release incorporates additional data sources and methodology refinements that improve how risk signals are weighted across title…
Global Pro AV Market Surges Toward USD 127.31 Billion by 2030, Led by Sony, Sams …
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025-2030.
According to Arizton research, the global pro AV market [https://www.arizton.com/market-reports/pro-av-market] was valued at USD 90.00 billion in 2024 and is projected to reach USD 127.31 billion by 2030, growing at a CAGR of 5.95% during the forecast period.
Explore the Full Market Insights: https://www.arizton.com/market-reports/pro-av-market
Report Summary:
Market Size (2030): USD 127.31 Billion
Market Size (2024): USD 90.00 Billion
CAGR (2024-2030): 5.95%
Historic…
Redway Power Launches High-Capacity 51.2V 420Ah Lithium Forklift Battery for Nex …
Redway Power, a leading OEM lithium battery manufacturer, proudly announces the launch of its latest innovation: the 51.2V 420Ah Lithium Forklift Battery [https://www.redwaypower.com/product/48v-420ah-forklift-lithium-battery/]. Designed for modern industrial operations, this next-generation battery combines high capacity, advanced safety features, and customizable OEM/ODM solutions to revolutionize warehouse productivity and material handling efficiency.
Introducing Next-Generation Power for Forklifts
The new 51.2V 420Ah battery is engineered to deliver exceptional energy efficiency and durability. With a nominal energy…
More Releases for Oncolytic
Prominent Oncolytic Virus Therapy Market Trend for 2025: Accelerating Oncolytic …
Which drivers are expected to have the greatest impact on the over the oncolytic virus therapy market's growth?
The rise in cancer incidences is likely to fuel the expansion of the oncolytic virus therapy market. Oncolytic virus therapy is gaining traction as an appealing approach to treating cancer- a collection of diseases marked by abnormal cell growth and proliferation. This therapeutic strategy effectively targets and eliminates cancer cells, while also triggering…
Enhancing the Immune Response with Oncolytic Virus Therapy
Oncolytic virus therapy is revolutionizing cancer treatment by harnessing the unique characteristics of viruses to specifically target and destroy cancer cells. This cutting-edge approach represents a significant advancement in cancer care, offering renewed hope for patients with different types of cancer.
Download Report:
https://www.kuickresearch.com/report-oncolytic-virus-immunotherapy-market-oncolytic-virus-therapy-market-oncolytic-virus-fda-approved-oncolytic-virus-clinical-trilas
The essence of oncolytic virus therapy is based on genetically modified viruses that can selectively attack and kill cancer cells while leaving healthy tissue unharmed. These engineered viruses take…
Creative Biolabs Unleashes Solutions to Validate Oncolytic Virotherapy
Creative Biolabs introduces safety and efficacy validation strategies for oncolytic virotherapy.
New York, USA - June 17, 2024 - Oncolytic virotherapy appears as a new paradigm in cancer immunotherapy that enrolls specifically engineered viruses to selectively infect and kill cancer cells, some of which have marched into clinical trials, like adenoviruses, HSV, reovirus, vaccinia virus, and measles. With so many other candidates still on their preclinical journey, the requests to validate…
Oncolytic Virus Competitive Landscape 2023 (Updated)
DelveInsight's, "Oncolytic Virus Competitive Landscape 2023" report provides comprehensive insights about 150+ Oncolytic Virus Companies and 175+ drugs in the Oncolytic Virus Competitive landscape. It covers the Oncolytic Virus therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Oncolytic Virus Competitive Landscape Report
• DelveInsight's Oncolytic Virus report depicts a robust space with 150+ Oncolytic…
Oncolytic Virus Therapy Market Oncolytic Virus Therapy Clinical Pipeline Report …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Oncolytic Virus
1.1 Outline of Oncolytic Virotherapy
1.2 Trail from Genesis to Biogenetics
Primer of Virotherapy in Malignancies
2.1 Oncolytic Viruses towards Cancer
2.2 Approaches for Targeting Tumor Cells
2.2.1 Pro Apoptotic Targeting
2.2.2 Translational Targeting
2.2.3 Transcriptional Targeting
2.2.4 Transductional Targeting
Mechanism…
Global Oncolytic Virus Therapy Report Highlight Market Opportunity & Insight On …
“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic…
